Xentech Seeks to Fund €4M Development Plan
BioWorld International Correspondent
PARIS - Xentech, a contract research start-up specialized in evaluating the efficacy of anticancer therapies, raised seed capital of €600,000 (US$765,000) from Aurinvest Capital 2, indicating that would help it put together a €4 million development plan.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST